Anti-VZV Recombinant Antibody (DDF2-VZV2) (CAT#: MRO-1154LC)

Figure 1 shows the VZV binding activity for the preparation of recombinant phage expressing DDF-VZV1 (VZV-1), DDF-VZV2 (VZV-2), or unrelated human Fab (e-137) used as a negative control.

The binding activity was measured in ELISA using the indicated antigen used for plate coating in the form of whole protein extract (for MRC-5 cells) or purified protein (bovine serum albumin, for BSA).

Antibodies specific for varicella zoster virus

Figure 2 shows immunofluorescence and staining by DDF-VZV1 (A) and DDF-VZV2 (B) of VZV-infected MRC-5 cells.

Cell membranes are indicated by white lines and nuclear membranes by dotted white lines. The Fab on the uninfected cells was used to obtain unstained.

Antibodies specific for varicella zoster virus

Figure 3 shows VZV neutralizing activity against DDF-VZV1 (A) and DDF-VZV2 (B), as expressed as partially purified human recombinant Fabs shown on phage coat proteins.

Dose-response analysis of plaque reduction was performed in parallel with the corresponding concentrations of unrelated human Fab (e137).

Antibodies specific for varicella zoster virus

Figure 4 shows VZV neutralizing activity against human Fab DDF-VZV1 and DDF-VZV2 as expressed and purified using the pDLac system.

Each Fab was used at the indicated concentration and plaque reduction was calculated.

Antibodies specific for varicella zoster virus